Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
10:07:04 EDT Thu 02 May 2024
Enter Symbol
or Name
USA
CA



Q:CBAY - CYMABAY THERAPEUTICS INC - http://www.calbayinternational.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CBAY - QHALTED32.48    32.50  7.2609Mar 21Mar 2215 min RT 2¢

Recent Trades - All 0 today
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-03-22 09:18U:CBAYNews ReleaseGilead Sciences Announces Completion of Acquisition of CymaBay
2024-03-04 08:00U:CBAYNews ReleaseCymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis
2024-02-28 16:45U:CBAYNews ReleaseCymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update
2024-02-21 17:43U:CBAYNews ReleaseThe New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary Cholangitis
2024-02-20 16:05U:CBAYNews ReleaseCymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-12 08:45U:CBAYNews ReleaseCymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis
2024-02-12 08:30U:CBAYNews ReleaseGilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
2024-01-31 08:00U:CBAYNews ReleaseCymaBay Therapeutics to Participate in Upcoming Investment Conferences
2024-01-16 16:29U:CBAYNews ReleaseCymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-03 08:00U:CBAYNews ReleaseNew Published Data Demonstrates Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement in Primary Biliary Cholangitis in Phase 3 Post-Hoc Analysis of CymaBay's Seladelpar
2024-01-02 08:00U:CBAYNews ReleaseCymaBay Therapeutics to Present at the 42nd Annual JP Morgan Healthcare Conference 2024
2023-12-18 16:05U:CBAYNews ReleaseCymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-12-15 08:00U:CBAYNews ReleaseCymaBay Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary Cholangitis
2023-11-17 16:15U:CBAYNews ReleaseCymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-13 08:00U:CBAYNews ReleaseCymaBay Announces an Oral Presentation of Seladelpar Phase 3 Pivotal Results in Primary Biliary Cholangitis at the Late Breaker Session of the Liver Meeting ‚ ®
2023-11-07 16:04U:CBAYNews ReleaseCymaBay Reports Third Quarter and Nine Months Ended September 30, 2023 Financial Results and Provides Corporate Update
2023-11-06 08:00U:CBAYNews ReleaseCymaBay Therapeutics to Present at Upcoming Investment Conferences
2023-11-01 08:00U:CBAYNews ReleaseCymaBay Announces Publication of Two-year Safety and Efficacy Results of Seladelpar in Patients with Primary Biliary Cholangitis
2023-10-31 16:05U:CBAYNews ReleaseCymaBay Therapeutics to Report Third Quarter of 2023 Financial Results on Tuesday, November 7, 2023
2023-10-23 16:05U:CBAYNews ReleaseCymaBay Presents Results on the Potential of Seladelpar in Treatment of Patients with Primary Biliary Cholangitis at ACG 2023